SCHEMBL5963534

SCHEMBL5963534

CC(C)(C)OC(=O)N1C(=O)[C@H](O)[C@@H]1c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.44
ABCB1 P08183 1/20 0.43
KLK7 P49862 6/20 0.42
RORC P51449 2/20 0.41
GPR119 Q8TDV5 1/20 0.40
BCHE P06276 1/20 0.39
KLK5 Q9Y337 5/20 0.39
RIPK1 Q13546 2/20 0.39
NR1H2 P55055 3/20 0.39
RXRA P19793 2/20 0.39
NR1H3 Q13133 2/20 0.39
PRSS1 P07477 2/20 0.38
PRSS2 P07478 2/20 0.38
PRSS3 P35030 2/20 0.38
STS P08842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14050230 1.00 ELANE (0.44) ELANEABCB1KLK7RORCGPR119
SCHEMBL16237822 1.00 ELANE (0.44) ELANEABCB1KLK7RORCGPR119
SCHEMBL9924398 0.85 ELANE (0.44) ELANEABCB1KLK7RORCGPR119
SCHEMBL14199221 0.85 ELANE (0.44) ELANEABCB1KLK7RORCGPR119
SCHEMBL5963538 0.83 ELANE (0.51) ELANEABCB1
SCHEMBL8952612 0.83 ABCB1 (0.47) ELANEABCB1KLK7RORCGPR119
SCHEMBL7735385 0.83 ABCB1 (0.47) ELANEABCB1KLK7RORCGPR119
SCHEMBL8952629 0.83 ABCB1 (0.47) ELANEABCB1KLK7RORCGPR119
SCHEMBL8952619 0.83 ABCB1 (0.47) ELANEABCB1KLK7RORCGPR119
SCHEMBL4961152 0.81 ABCB1 (0.43) ELANEABCB1KLK7RORCGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567312-B2 Cabazitaxel, related compounds and methods of synthesis SHANGHAI BIOMAN PHARMA LTD (CN) 2017-02-14 US disclosed
US-8658811-B2 Process for the preparation of docetaxel, its intermediates, and methods for preparation thereof SHANGHAI PARLING PHARMA-TECH. CO., LTD. (CN) 2014-02-25 US disclosed
WO-2012088391-A1 NON-RING HYDROXY SUBSTITUTED TAXANES AND METHODS FOR SYNTHESIZING THE SAME NEKTAR THERAPEUTICS (US) 2012-06-28 WO disclosed
US-20100228038-A1 PROCESSES FOR THE PRODUCTION OF POLYCYCLIC FUSED RING COMPOUNDS FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-09-09 US disclosed
US-7667055-B2 Processes for the production of polycyclic fused ring compounds FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-02-23 US disclosed
US-7550608-B2 Processes for the preparation of docetaxel FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2009-06-23 US disclosed
US-7541458-B2 β-lactam synthesis FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2009-06-02 US disclosed
US-7358378-B2 Processes for the preparation of paclitaxel FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2008-04-15 US disclosed
EP-0681568-B1 PROCESS FOR PREPARATION OF TAXANE DERIVATIVES AND BETA-LACTAM INTERMEDIATES THEREFOR UNIV NEW YORK STATE RES FOUND (US) 2006-07-26 EP disclosed
US-6218553-B1 METALLIZATION BY REACTING A BACCATIN III DERIVATIVE WITH A METAL ALKYLDISILAZIDE THE STATE UNIVERSITY OF NEW YORK AT STONY BROOK 2001-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228038-A1 PROCESSES FOR THE PRODUCTION OF POLYCYCLIC FUSED RING COMPOUNDS COASY, PARG, PIN4 ELANE 4817/4885ABCB1 2404/4885KLK7 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.